DDInter1078 DDInter915
Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Lisdexamfetamine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Epinephrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Labetalol
Labetalol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Lisdexamfetamine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Lisdexamfetamine (Compound) resembles Labetalol (Compound) and Labetalol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)